IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob L who wrote (1711)	5/30/2000 3:55:00 AM
From: Maurice Winn	1 Recommendation of 1762

<...In a similar study in intermediate- or high-grade patients, the overall response rate was 97%, with 20 of 33 patients achieving complete responses. As a follow-up to these studies, Genentech and IDEC launched a 420-patient phase III study in January 2000 to evaluate safety and efficacy of Rituxan/CHOP versus CHOP alone in previously untreated CD20+ intermediate- or high-grade NHL patients. > The wheels grind verrrryyyyy slowly. Rituxan has been available to oncologists to kill CD20 lymphoma cells for 30 months now. They are gradually working up a head of steam...unbelievably slowly. Imagine how many umpty trillions of cancer cells have been given a free run for all those months while oncologists figure out that Rituxan might be useful to keep people alive. Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next